SCHEMBL25003569

SCHEMBL25003569

CC(C)C(=O)[C@@H](N)CCCCNC(=O)OCc1ccccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 3/20 0.56
NFE2L2 Q16236 3/20 0.56
ANPEP P15144 1/20 0.48
DPP8 Q6V1X1 3/20 0.47
DPP7 Q9UHL4 3/20 0.47
DPP4 P27487 2/20 0.45
DPP9 Q86TI2 2/20 0.45
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
CYP2C19 P33261 1/20 0.42
MAPT P10636 2/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 2/20 0.42
MEN1 O00255 1/20 0.42
PKM P14618 1/20 0.42
CASP3 P42574 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3925964 0.88 KEAP1 (0.58) KEAP1NFE2L2ANPEPDPP8DPP7
SCHEMBL30600458 0.88 KEAP1 (0.58) KEAP1NFE2L2ANPEPDPP8DPP7
SCHEMBL4413196 0.88 KEAP1 (0.58) KEAP1NFE2L2ANPEPDPP8DPP7
SCHEMBL9331674 0.88 KEAP1 (0.58) KEAP1NFE2L2ANPEPDPP8DPP7
SCHEMBL17073673 0.88 KEAP1 (0.58) KEAP1NFE2L2ANPEPDPP8DPP7
SCHEMBL29400837 0.85 KEAP1 (0.57) KEAP1NFE2L2ANPEPDPP8DPP7
SCHEMBL30600462 0.85 KEAP1 (0.57) KEAP1NFE2L2ANPEPDPP8DPP7
SCHEMBL6281421 0.84 DPP8 (0.59) KEAP1NFE2L2ANPEPDPP8DPP7
SCHEMBL5204177 0.84 KEAP1 (0.54) KEAP1NFE2L2ANPEPDPP8DPP7
SCHEMBL9752156 0.84 KEAP1 (0.54) KEAP1NFE2L2ANPEPDPP8DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230045142-A1 SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES THE JOHNS HOPKINS UNIVERSITY (US) 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230045142-A1 SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES MRPS23, RPP30, RPS19 KEAP1 1826/4885NFE2L2 3000/4885ANPEP 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.